Pfizer experienced record revenue from its coronavirus products a few years back, but growth has slowed. The company is now focusing on new products and oncology to drive revenue in the future. Pfizer’s revenue peaked at over $100 billion in 2022, but has since faced declines due to decreased demand for coronavirus products. The company is implementing a cost realignment plan to save over $7 billion by 2027. Pfizer is launching new drugs and acquisitions to offset upcoming patent expirations. The company predicts $20 billion in revenue from new launches by 2030 and aims to become a leader in oncology treatment.

Read more at Nasdaq: Where Will Pfizer Be in 5 Years?